ERNA — Ernexa Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 748592 ·
Last close
$1.63
Market Cap
$2.66M
52W High
$38.00
52W Low
$1.57
ADV30
46,270
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -2,990,000 -2,941,000 7,104,000 5,575,000 2,753,000
Jun 2026 0 — -4,104,000 -4,009,000 6,315,000 5,028,000 3,115,000
Mar 2026 0 0 -3,546,000 -5,506,000 10,543,000 9,177,000 3,684,000
Dec 2025 0 0 -2,094,000 -1,502,000 5,834,000 1,884,000 3,433,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,836,000
Investing CF
$-42,000
Financing CF
$9,591,000
CapEx
$-20,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-29.29
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-255,159,000
Inventory
—
Receivables
$83,000
ST Investments
—
EBIT TTM
$-16,520,000
Pretax Income TTM
$-12,353,000
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,319,000 -14,084,000 5,830,000 3,433,000 2,401,000 -7,017,000
Dec 2024 582,000 -17,250,000 -44,539,000 5,269,000 3,568,000 1,701,000 -15,836,000
Dec 2023 68,000 -20,675,000 -21,668,000 49,132,000 46,899,000 2,233,000 -20,408,000
Dec 2022 0 -26,947,000 -24,579,000 22,279,000 10,172,000 12,107,000 -20,976,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-12,258,000
OpCashFlow TTM
—
Assets (Latest)
$6,315,000
Forward EPS
$-9.60

Peers — same industry

TickerNameMarket CapLastDaily %
BIXT BIOXYTRAN, INC $2.66M $0.02 —
NXTS Nexentis Technologies Inc. $2.65M $1.82 —
MBIO MUSTANG BIO, INC. $2.63M $0.39 —
EOCN EoCene Ltd. $2.63M $2.46 —
PPBT PURPLE BIOTECH LTD. $2.78M $1.71 —

News headlines (Yahoo Finance, 1h cache)

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
2026-10-22 12:53 · Yahoo
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
2026-10-12 20:05 · Yahoo
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
2026-10-06 12:55 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
2026-10-01 13:20 · Yahoo
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
2026-09-30 12:32 · Yahoo
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
2026-09-29 13:15 · Yahoo
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
2026-09-17 12:42 · Yahoo
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-14 13:05 · Yahoo
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.